Patents by Inventor Audrey LARUE-TRIOLET

Audrey LARUE-TRIOLET has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Prediction of the risk of developing a disseminated infection for patients admitted to an intensive care unit
    Patent number: 10466255
    Abstract: A method for predicting the risk of developing a disseminated infection in a patient admitted to intensive care having no clinical symptoms of such infection includes: determining a first dose of gelsolin G1 in a biological sample from the patient originating from a first sample taken at time T1, carried out between the day of intensive care admission and 48 hours afterward; determining a second dose of gelsolin G2 in a biological sample from the patient originating from a second sample taken at time T2, carried out two to three days after the first sampling; calculating the variation between the dose of gelsolin G2 and the dose of gelsolin G1, giving a ? value; and comparing the ? value to a threshold value S determined beforehand from two patient populations admitted to intensive care, one not having developed a disseminated infection and the other having developed such an infection.
    Type: Grant
    Filed: May 11, 2016
    Date of Patent: November 5, 2019
    Assignees: BIOMERIEUX, HOSPICES CIVILS DE LYON, CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES
    Inventors: Bernard Allaouchiche, Karim Asehnoune, Marilyne Dupin, Tanguy Fortin, Aurélie Gouel-Cheron, Audrey Larue-Triolet, Guillaume Monneret, Alexandre Pachot, Sylvie Pons, Antoine Roquilly, Fabienne Venet
  • PREDICTION OF THE RISK OF DEVELOPING A DISSEMINATED INFECTION FOR PATIENTS ADMITTED TO AN INTENSIVE CARE UNIT
    Publication number: 20180095094
    Abstract: A method for predicting the risk of developing a disseminated infection in a patient admitted to intensive care having no clinical symptoms of such infection includes: determining a first dose of gelsolin G1 in a biological sample from said patient originating from a first sample taken at time T1, carried out between the day of intensive care admission and 48 hours afterward; determining a second dose of gelsolin G2 in a biological sample from said patient originating from a second sample taken at time T2, carried out two to three days after the first sampling; calculating the variation between the dose of gelsolin G2 and the dose of gelsolin G1, giving a ? value; and comparing the ? value to a threshold value S determined beforehand from two patient populations admitted to intensive care, one not having developed a disseminated infection and the other having developed such an infection.
    Type: Application
    Filed: May 11, 2016
    Publication date: April 5, 2018
    Applicants: BIOMÉRIEUX, HOSPICES CIVILS DE LYON, CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES
    Inventors: Bernard ALLAOUCHICHE, Karim ASEHNOUNE, Marilyne DUPIN, Tanguy FORTIN, Aurélie GOUEL-CHERON, Audrey LARUE-TRIOLET, Guillaume MONNERET, Alexandre PACHOT, Sylvie PONS, Antoine ROQUILLY, Fabienne VENET